Hypertension‐Mediated Organ Damage: Pathophysiological Mechanisms, Clinical Consequences, and Implications for Early Risk Stratification

ABSTRACT Hypertension‐mediated organ damage (HMOD) represents a critical and dynamic stage on the cardiovascular continuum, serving as the primary mechanistic link between sustained arterial pressure elevation and major adverse cardiovascular and renal events. HMOD is often subclinical at first occurrence and is a systemic, cumulative process, representing structural and functional injury of the heart, brain, kidneys, and vasculature. This narrative review synthesises current evidence on the pathogenesis and clinical sequelae of HMOD, specifically focusing on the interplay between chronic haemodynamic load, endothelial dysfunction, oxidative stress, neurohormonal activation, inflammation, and microvascular remodelling. Key manifestations such as left ventricular hypertrophy, hypertensive nephrosclerosis, cerebral small vessel disease, and arterial stiffness can be regarded as dynamic and partly modifiable phenomena of subclinical injury rather than inevitable sequelae of long‐standing hypertension. This review aims to summarise contemporary detection and risk stratification approaches, drawing on the 2023 European Society of Hypertension (ESH) and 2024 European Society of Cardiology (ESC) guidelines, combining imaging and biomarker‐based assessment. Evidence supporting organ protection as an important therapeutic objective is also reviewed, with particular attention to regression of left ventricular mass and reduction in albuminuria as treatment endpoints associated with improved prognosis beyond blood pressure reduction alone. Finally, unresolved issues such as causal versus associative properties of candidate biomarkers, comparative validity of vascular indices, and heterogeneity in organ‐specific response to therapy are critically analysed. The overarching goal of this review is to support a clinically applicable framework for early HMOD detection and organ‐protective treatment strategies in routine hypertension care.

Authors

Institutions

Publication Details

Journal
Clinical and Experimental Pharmacology and Physiology
Published
2026-06-18
DOI
https://doi.org/10.1111/1440-1681.70142
Primary Topic
Blood Pressure and Hypertension Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Hypertension‐Mediated Organ Damage: Pathophysiological Mechanisms, Clinical Consequences, and Implications for Early Risk Stratification

Ali Hussein Choker
Clinical and Experimental Pharmacology and Physiology
Blood Pressure and Hypertension Studies
article

Hypertension‐Mediated Organ Damage: Pathophysiological Mechanisms, Clinical Consequences, and Implications for Early Risk Stratification

Ali Hussein Choker
article en

Abstract

ABSTRACT Hypertension‐mediated organ damage (HMOD) represents a critical and dynamic stage on the cardiovascular continuum, serving as the primary mechanistic link between sustained arterial pressure elevation and major adverse cardiovascular and renal events. HMOD is often subclinical at first occurrence and is a systemic, cumulative process, representing structural and functional injury of the heart, brain, kidneys, and vasculature. This narrative review synthesises current evidence on the pathogenesis and clinical sequelae of HMOD, specifically focusing on the interplay between chronic haemodynamic load, endothelial dysfunction, oxidative stress, neurohormonal activation, inflammation, and microvascular remodelling. Key manifestations such as left ventricular hypertrophy, hypertensive nephrosclerosis, cerebral small vessel disease, and arterial stiffness can be regarded as dynamic and partly modifiable phenomena of subclinical injury rather than inevitable sequelae of long‐standing hypertension. This review aims to summarise contemporary detection and risk stratification approaches, drawing on the 2023 European Society of Hypertension (ESH) and 2024 European Society of Cardiology (ESC) guidelines, combining imaging and biomarker‐based assessment. Evidence supporting organ protection as an important therapeutic objective is also reviewed, with particular attention to regression of left ventricular mass and reduction in albuminuria as treatment endpoints associated with improved prognosis beyond blood pressure reduction alone. Finally, unresolved issues such as causal versus associative properties of candidate biomarkers, comparative validity of vascular indices, and heterogeneity in organ‐specific response to therapy are critically analysed. The overarching goal of this review is to support a clinically applicable framework for early HMOD detection and organ‐protective treatment strategies in routine hypertension care.

Clinical and Experimental Pharmacology and PhysiologyVol. 53(7)
Free University of Tbilisi (GE)
Good health and well-being
Openalex Percentile: Top 7%
Blood Pressure and Hypertension Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Hypertension‐Mediated Organ Damage: Pathophysiological Mechanisms, Clinical Consequences, and Implications for Early Risk Stratification — Ali Hussein Choker · Clinical and Experimental Pharmacology and Physiology (2026) | TGRS Research Map | TGRS